Pipeline

Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology.

Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Clinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones
  • RVU120
    CDK8/19
    • R/R AML/HR-MDS (RIVER-52) (monotheraphy)

    • Updated Ph II data in 2Q25
      (enrollment suspended)

      ​

    • R/R AML (RIVER-81) (combination therapy)

    • Updated Ph II data in 2Q25

      ​

    • LR-MDS (REMARK) (monotherapy)

    • Initial Ph II data in 4Q25

    • Myelofibrosis (POTAMI-61) (monotherapy and combo)

    • Initial Ph II data in 2Q25

  • Dapolsertib MEN1703(SEL24
    PIM/FLT3
    • DLBCL (JASPIS-01)

    • Ph II initiation in 1Q25

      ​

  • RVU305 (PRMT5)
    • MTAP-deleted tumors

    • Complete IND/CTA
      -enabling studies in 2H25

Discovery & Preclinical Projects

  • Program/ Target Name
  • Indication
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Partner
  • Anticipated
    Milestones

Ryvu Technology

  • ADCs – NOVEL PAYLOADS
    • ONCOLOGY
  • ONCO PRIME – PRECISION MEDICINE
    • ONCOLOGY

Platform collaborations

  • IMMUNE MODULATION
    • ONCOLOGY
  • STING ADC
    • ONCOLOGY